Zurich/Bergisch Gladbach - Lino Biotech has been acquired by the German biotechnology company Miltenyi Biotec. The headquarters at the spin-off from the Swiss Federal Institute of Technology Zurich founded in 2020 will be converted for research and development.

According to a press release, lino Biotech based in Zurich has been acquired by the global biotechnology and biomedicine company Miltenyi Biotec with headquarters in Bergisch Gladbach. Lino Biotech AG is a life science company that develops reagent-free biosensors and readers to directly measure pharmaceutically relevant biologic units from raw samples. Lino Biotech calls this proprietary technology Focal Molography. It is the only provider of this in the world.

The company was founded as a spin-off from the Swiss Federal Institute of Technology Zurich (ETH Zurich) in March 2020. According to the company’s own information, it has made “significant advances” in developing new biosensors. These make it easier to perform quality control in the bioprocess industry, measure viral load in the manufacture of cell and gene therapies, and test off-target reactions in living cells to support pharmaceutical research. The development study was also published in 2020.

Lino’s CEO Dr. Mirko Stange comments: “Lino’s innovative biosensor platform and Miltenyi's cell and gene therapy approaches offer exciting synergies to lower the cost and establish a new standard for potency assays.” According to the press release, lino’s headquarters in Zurich will be further developed for research and chip and application development.

Within the framework of the acquisition, Miltenyi Biotech will take on 100 percent of investors’ shares, including the Roche Venture Fund and the High-Tech Gründerfonds. There are no further details regarding the transaction. mm

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?